Related Experiment Video
Updated: Jan 2, 2026
Facile Preparation of 4-Substituted Quinazoline Derivatives
Published on: February 15, 2016
Design, synthesis, and enzymatic characterization of quinazoline-based CYP1A2 inhibitors
Pedro A Corral1, Jordy F Botello1, Chengguo Xing1
1Department of Medicinal Chemistry, College of Pharmacy, University of Florida, Gainesville, FL 32610, United States.
Abstract:
Cytochrome P450 isozyme 1A2 (CYP1A2) is one main xenobiotic metabolizing enzyme in humans. It has been associated with the bioactivation of procarcinogens, including 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK), a tobacco specific and potent pulmonary carcinogen. This work describes the computational design and in-silico screening of potential CYP1A2 inhibitors, their chemical synthesis, and enzymatic characterization with the ultimate aim of assessing their potential as cancer chemopreventive agents. To achieve this, a combined classifiers model was used to screen a library of quinazoline-based molecules against known CYP1A2 inhibitors, non-inhibitors, and substrates to predict which quinazoline candidates had a better probability as an inhibitor. Compounds with high probability of CYP1A2 inhibition were further computationally evaluated via Glide docking. Candidates predicted to have selectivity and high binding affinity for CYP1A2 were synthesized and assayed for their enzymatic inhibition of CYP1A2, leading to the discovery of novel and potent quinazoline-based CYP1A2 inhibitors.
Insights
Researchers computationally designed and screened quinazoline molecules to find new inhibitors of Cytochrome P450 isozyme 1A2 (CYP1A2). This enzyme activates tobacco carcinogens, so inhibiting it may offer cancer chemoprevention strategies.
Area of Science:
- Biochemistry
- Pharmacology
- Computational Chemistry
Background:
- Cytochrome P450 isozyme 1A2 (CYP1A2) is a key human enzyme involved in metabolizing foreign compounds.
- CYP1A2 plays a role in activating procarcinogens like NNK, a tobacco-specific pulmonary carcinogen.
Purpose of the Study:
- To computationally design and screen potential CYP1A2 inhibitors.
- To synthesize and enzymatically characterize novel quinazoline-based compounds.
- To assess the potential of these compounds as cancer chemopreventive agents.
Main Methods:
- Utilized a combined classifiers model for in-silico screening of quinazoline-based molecules against CYP1A2.
- Employed Glide docking to evaluate binding affinity and selectivity of promising candidates.
- Synthesized selected compounds and performed enzymatic assays to determine CYP1A2 inhibition.
Main Results:
- Identified quinazoline-based molecules with high predicted probability of CYP1A2 inhibition.
- Discovered novel compounds demonstrating potent inhibition of CYP1A2 enzymatic activity.
- Validated computational predictions through experimental synthesis and characterization.
Conclusions:
- The study successfully identified novel and potent quinazoline-based CYP1A2 inhibitors using computational design and in-silico screening.
- These findings support the potential of these compounds as cancer chemopreventive agents by targeting CYP1A2-mediated carcinogen activation.
Related Concept Videos
01:30Enzyme Inhibition
01:28Structure-Activity Relationships and Drug Design
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...